JP2022512851A5 - - Google Patents
Info
- Publication number
- JP2022512851A5 JP2022512851A5 JP2021523335A JP2021523335A JP2022512851A5 JP 2022512851 A5 JP2022512851 A5 JP 2022512851A5 JP 2021523335 A JP2021523335 A JP 2021523335A JP 2021523335 A JP2021523335 A JP 2021523335A JP 2022512851 A5 JP2022512851 A5 JP 2022512851A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024178276A JP2025004212A (ja) | 2018-11-05 | 2024-10-10 | がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862755805P | 2018-11-05 | 2018-11-05 | |
| US62/755,805 | 2018-11-05 | ||
| PCT/US2019/059581 WO2020096915A1 (en) | 2018-11-05 | 2019-11-04 | Dosing regimen of anti-tigit antibody for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024178276A Division JP2025004212A (ja) | 2018-11-05 | 2024-10-10 | がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512851A JP2022512851A (ja) | 2022-02-07 |
| JPWO2020096915A5 JPWO2020096915A5 (https=) | 2022-11-16 |
| JP2022512851A5 true JP2022512851A5 (https=) | 2022-11-16 |
Family
ID=70611082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523335A Pending JP2022512851A (ja) | 2018-11-05 | 2019-11-04 | がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン |
| JP2024178276A Withdrawn JP2025004212A (ja) | 2018-11-05 | 2024-10-10 | がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024178276A Withdrawn JP2025004212A (ja) | 2018-11-05 | 2024-10-10 | がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210403557A1 (https=) |
| EP (1) | EP3877418A4 (https=) |
| JP (2) | JP2022512851A (https=) |
| KR (1) | KR20210091209A (https=) |
| CN (1) | CN113302204A (https=) |
| AU (1) | AU2019375409A1 (https=) |
| BR (1) | BR112021008582A8 (https=) |
| CA (1) | CA3118964A1 (https=) |
| MX (1) | MX2021005236A (https=) |
| WO (1) | WO2020096915A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CN115916348A (zh) * | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| US20240262915A1 (en) * | 2020-09-22 | 2024-08-08 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-tigit antibody and double antibody and their application |
| EP4384550A4 (en) * | 2021-08-10 | 2025-06-18 | Merck Sharp & Dohme LLC | THERAPEUTIC COMBINATION WITH A TIGIT ANTAGONIST, A PD-1 ANTAGONIST AND LENVATINIB |
| KR20240047393A (ko) * | 2021-08-10 | 2024-04-12 | 머크 샤프 앤드 돔 엘엘씨 | Tigit 길항제, pd-1 길항제 및 화학요법제(들)를 포함하는 치료 조합물 |
| WO2024211551A1 (en) | 2023-04-06 | 2024-10-10 | Glaxosmithkline Intellectual Property (No.4) Limited | Methods for treating and monitoring cancer |
| WO2025128499A1 (en) * | 2023-12-12 | 2025-06-19 | Merck Sharp & Dohme Llc | Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer |
| CN118671353A (zh) * | 2024-05-30 | 2024-09-20 | 中国人民解放军总医院第一医学中心 | 用于ais诊断的生物标志物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968488A1 (en) * | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| AU2015305754B2 (en) * | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| CN107207594B (zh) * | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| TN2017000440A1 (en) * | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| CA2994858C (en) * | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| AU2017269675A1 (en) * | 2016-05-26 | 2019-01-17 | Merck Patent Gmbh | PD-1 / PD-L1 inhibitors for cancer treatment |
| SMT202300418T1 (it) * | 2017-05-30 | 2024-01-10 | Bristol Myers Squibb Co | Trattamento di tumori positivi per lag-3 |
| WO2019152574A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
-
2019
- 2019-11-04 MX MX2021005236A patent/MX2021005236A/es unknown
- 2019-11-04 US US17/288,641 patent/US20210403557A1/en not_active Abandoned
- 2019-11-04 BR BR112021008582A patent/BR112021008582A8/pt unknown
- 2019-11-04 CN CN201980087763.5A patent/CN113302204A/zh active Pending
- 2019-11-04 WO PCT/US2019/059581 patent/WO2020096915A1/en not_active Ceased
- 2019-11-04 KR KR1020217017162A patent/KR20210091209A/ko not_active Withdrawn
- 2019-11-04 EP EP19881474.1A patent/EP3877418A4/en active Pending
- 2019-11-04 CA CA3118964A patent/CA3118964A1/en active Pending
- 2019-11-04 AU AU2019375409A patent/AU2019375409A1/en active Pending
- 2019-11-04 JP JP2021523335A patent/JP2022512851A/ja active Pending
-
2024
- 2024-10-10 JP JP2024178276A patent/JP2025004212A/ja not_active Withdrawn